LncRNA NR2F2-AS1 positively regulates CDK4 to promote cancer cell proliferation in prostate carcinoma

References

• Wong MCS, Goggins WB, Wang HHX, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–874.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Lindberg J, Kristiansen A, Wiklund P, et al. Tracking the origin of metastatic prostate cancer. Eur Urol. 2015;67(5):819–822.
   PubMed Web of Science ®Google Scholar
• Qian S, Xia J, Liu H, et al. Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer. Aging Male. 2018;21(4):231–237.
   PubMed Web of Science ®Google Scholar
• Torrealba N, Vera R, Fraile B, et al. TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer. Aging Male. 2019;11:1–11.
   Web of Science ®Google Scholar
• Torrealba N, Rodriguez-Berriguete G, Fraile B, et al. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer. Aging Male. 2018;21(3):211–222.
   PubMed Web of Science ®Google Scholar
• Russo GI, Calogero AE, Condorelli RA, et al. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male. 2018;23:1–7.
   PubMed Web of Science ®Google Scholar
• Zhang P, Su XJ, Hu WL, et al. Letter to the Editor involving in the article “Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia”. Aging Male. 2018;21(3):223.
   PubMed Web of Science ®Google Scholar
• Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 2013;40(3):244–258.
   PubMed Web of Science ®Google Scholar
• Rolfo A, Giuffrida D, Giuffrida MC, et al. New perspectives for prostate cancer treatment: in vitro inhibition of LNCaP and PC3 cell proliferation by amnion-derived mesenchymal stromal cells conditioned media. Aging Male. 2014;17(2):94–101.
   PubMed Web of Science ®Google Scholar
• Sahin S, Karataş F. Plasma thiols in prostate cancer. Aging Male. 2019;28:1.
   Google Scholar
• Yassin A, Salman M, Talib RA, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20(2):125–133.
   PubMed Web of Science ®Google Scholar
• Topaktaş R, Ürkmez A, Kutluhan MA, et al. Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20 ng/ml? Aging Male. 2019;10:1–5.
   Web of Science ®Google Scholar
• López-Guarnido O, Urquiza-Salvat N, Saiz M, et al. Bioactive compounds of the Mediterranean diet and prostate cancer. Aging Male. 2018;21(4):251–260.
   PubMed Web of Science ®Google Scholar
• Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24(18):1967–2000.
   PubMed Web of Science ®Google Scholar
• Tao ZQ, Shi AM, Wang KX, et al. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;19(5):805–812.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez C, Gelbert LM, Lallena MJ, et al. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett. 2015;25(17):3420–3435.
   PubMed Web of Science ®Google Scholar
• Li JL, Li R, Gao Y, et al. LncRNA CCAT1 promotes the progression of preeclampsia by regulating CDK4. Eur Rev Med Pharmacol Sci. 2018;22(5):1216
   PubMed Web of Science ®Google Scholar
• Gu S, Niu X, Mao F, et al. Long noncoding RNA PCA3 regulates glycolysis, viability and apoptosis by mediating the miR-1/CDK4 axis in prostate cancer. RSC Adv. 2018;8(66):37564–37572.
   PubMed Web of Science ®Google Scholar
• Engreitz JM, Haines JE, Perez EM, et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 2016;539(7629):452–455.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang X, Sun Q, et al. LncRNA NR2F2-AS1 promotes tumourigenesis through modulating BMI1 expression by targeting miR-320b in non-small cell lung cancer. J Cell Mol Med. 2019;23(3):2001–2011.
   PubMed Web of Science ®Google Scholar
• Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344(18):1373–1377.
   PubMed Web of Science ®Google Scholar
• Leyten GHJM, Hessels D, Smit FP, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res. 2015;21(13):3061–3070.
   PubMed Web of Science ®Google Scholar
• Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169–176.
   PubMed Web of Science ®Google Scholar
• Lulla AR, Slifker MJ, Zhou Y, et al. miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell-cycle arrest in colon cancer cells. Cancer Res. 2017;77(24):6902–6913.
   PubMed Web of Science ®Google Scholar
• Feng T, Xu D, Tu C, et al. MiR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4. Tumor Biol. 2015;36(8):5987–5997.
   PubMedGoogle Scholar
• Ahmed Amar SA, Eryilmaz R, Demir H, et al. Determination of oxidative stress levels and some antioxidant enzyme activities in prostate cancer. Aging Male. 2019;22(3):198–206.
   PubMed Web of Science ®Google Scholar
• Urquiza-Salvat N, Pascual-Geler M, Lopez-Guarnido O, et al. Adherence to Mediterranean diet and risk of prostate cancer. Aging Male. 2019;22(2):102–108.
   PubMed Web of Science ®Google Scholar
• Geler M, Urquiza-Salvat N, Cozar JM, et al. The influence of nutritional factors on prostate cancer incidence and aggressiveness. Aging Male. 2018;21(1):31–39.
   PubMed Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20(2):115–118.
   PubMed Web of Science ®Google Scholar